Tenaya Therapeutics Inc (TNYA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.68 (+1.06%), Market cap $0.19B, 52-week low–high $0.43 ~ $2.10.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regene
Financial statements, price targets, institutional (13F) holdings and related news for Tenaya Therapeutics Inc are updated in real time on BlackAll Trade.
Tenaya Therapeutics Inc trades at $0.68 (+1.06%). Real-time quotes and charts are available on BlackAll Trade.
Tenaya Therapeutics Inc has a market cap of about $0.19B.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gen